Currently, there are 492.80M common shares owned by the public and among those 486.02M shares have been available to trade.
Insiders at the company have transacted a total of 47 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 23 of these insider trades were purchases, accounting for 979,041 shares. Insider sales of the common stock occurred on 24 occasions, with total insider shares sold totaling 399,837 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 4.67% and 69.69% over the past three months. ELAN shares are trading 6.71% year to date (YTD), with the 12-month market performance up to 9.05% higher. It has a 12-month low price of $7.88 and touched a high of $15.94 over the same period. ELAN has an average intraday trading volume of 5.29 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.86%, 13.38%, and 40.52% respectively.
Institutional ownership of Elanco Animal Health Inc (NYSE: ELAN) shares accounts for 98.78% of the company’s 492.80M shares outstanding.
It has a market capitalization of $7.84B and a beta (3y monthly) value of 1.29. The earnings-per-share (ttm) stands at -$2.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.67% over the week and 3.09% over the month.
Analysts forecast that Elanco Animal Health Inc (ELAN) will achieve an EPS of $Elevai Labs, Inc. for the current quarter, $0.76 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Enliven Therapeutics, Inc. while analysts give the company a high EPS estimate of $Envela Corporation. Comparatively, EPS for the current quarter was $Eledon Pharmaceuticals, Inc. a year ago. Earnings per share for the fiscal year are expected to decrease by -17.30%, and -3.75% over the next financial year. EPS should shrink at an annualized rate of -4.00% over the next five years, compared to 28.42% over the past 5-year period.
Looking at the support for the ELAN, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on January 05, 2024, with the firm’s price target at $13-$20.
